Tocilizumab

證據等級: L5

預測適應症: 10 個

Tocilizumab: From Rheumatoid Arthritis to Ankylosing Spondylitis

One-Sentence Summary

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody with established use in rheumatoid arthritis. The TxGNN model predicts it may be effective for Ankylosing Spondylitis, but the underlying evidence base — 9 clinical trials and 20 publications — actually includes two terminated Phase 3 RCTs that failed to demonstrate efficacy, making this a mechanism-mismatch case rather than a supportive signal.

Quick Overview

Item	Content
Original Indication	Rheumatoid Arthritis (established global indication; not confirmed via Danish licensing data — see below)
Predicted New Indication	Ankylosing Spondylitis
TxGNN Prediction Score	99.99%
Evidence Level	L1
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank for this evidence pack. Based on known information, tocilizumab is a humanized monoclonal antibody that blocks the interleukin-6 receptor (IL-6R), and its efficacy in rheumatoid arthritis (RA) — where IL-6 plays a well-established pathogenic role — has been clinically proven.

However, the mechanistic rationale does not transfer cleanly to ankylosing spondylitis (AS). Axial spondyloarthritis, including AS, is primarily driven by the IL-17/IL-23 axis and TNF-α rather than IL-6 signaling. This is reflected directly in the evidence: two placebo-controlled Phase 2/3 RCTs of tocilizumab in AS (NCT01209689 and NCT01209702) were both terminated for lack of efficacy. The TxGNN high score most likely reflects knowledge-graph co-occurrence between tocilizumab and inflammatory joint disease broadly, rather than a pathway-specific signal for AS.

In short, this is a case where a high model score is contradicted by direct clinical trial evidence — the prediction should be treated as a cautionary example rather than a promising repurposing lead.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01209689	Phase 3	Terminated	113	RCT of tocilizumab vs. placebo in AS patients with inadequate response to prior TNF antagonists — terminated for lack of efficacy
NCT01209702	Phase 2/3	Terminated	306	Seamless RCT of tocilizumab vs. placebo in TNF-naïve AS patients who failed NSAIDs — terminated for lack of efficacy
NCT05670301	N/A	Recruiting	2500	Observational cytokine/biomarker profiling across systemic inflammatory diseases; not AS/tocilizumab-specific
NCT02925338	N/A	Completed	1431	Real-world observational study of Inflectra (infliximab biosimilar), not tocilizumab
NCT05696106	N/A	Unknown	750000	Registry study on risk of incident immune-mediated inflammatory diseases in biologics-treated patients
NCT07477795	Phase 2	Not yet recruiting	52	Secukinumab (not tocilizumab) in Takayasu arteritis
NCT02569736	N/A	Completed	60	Mechanistic study of tocilizumab’s effect on T follicular helper cells in RA patients
NCT07138898	Phase 2	Not yet recruiting	80	Perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty
NCT01965132	N/A	Recruiting	10000	Korean registry of biologics/targeted therapies across RA, AS and PsA — observational, not efficacy-specific

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23765873	2014	RCT	Annals of the Rheumatic Diseases	BUILDER-1/BUILDER-2 randomised placebo-controlled trials assessing short-term efficacy of tocilizumab in AS
22452603	2012	Review	Inflammation & Allergy Drug Targets	Reviews IL-6 antagonism rationale and limited evidence in AS
26986130	2016	Systematic Review	Medicine	Network meta-analysis comparing biologic regimens for AS
22450391	2012	Review	Current Opinion in Rheumatology	Treatment alternatives for AS refractory to TNF inhibition
20851032	2010	Case Report	Joint Bone Spine	Tocilizumab used in a patient with AS and Crohn’s disease refractory to TNF antagonists
33981717	2021	Case Report	Frontiers in Medicine	Tocilizumab for AA amyloidosis complicating AS (2 cases)
19822066	2009	Review	Clinical and Experimental Rheumatology	Compares biologics in RA vs. AS, noting differing pathogenesis
29278210	2017	Review	Current Pharmaceutical Biotechnology	Overview of biologics across RA, PsA and AS
28413099	2017	Review	Seminars in Arthritis and Rheumatism	Second-line biologic therapy optimization across RA/PsA/AS
29290076	2018	Cohort/Meta-analysis	Clinical Rheumatology	Serious infection risk with biologics in axial spondyloarthritis

Denmark Market Information

Tocilizumab currently has no marketing authorisation on file in this evidence pack (market status: Not marketed; 0 licenses recorded). No product-level authorisation data is available to summarize.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The only direct efficacy evidence for this indication — two Phase 2/3 RCTs (NCT01209689, NCT01209702) — was terminated for lack of efficacy, and the proposed mechanism (IL-6 blockade) does not align with the IL-17/TNF-driven pathogenesis of ankylosing spondylitis. The high TxGNN score is not corroborated by, and is directly contradicted by, existing clinical trial evidence.

To proceed, the following is needed:

TFDA/Danish SmPC warnings and contraindications (currently blocking safety assessment — flagged as a blocking data gap)
Confirmed DrugBank mechanism-of-action data to formally document the IL-6R pathway rationale
Re-review of BUILDER-1/BUILDER-2 (PMID 23765873) full trial results to confirm whether any subgroup showed partial benefit
If pursued despite Hold status, a documented rationale for why this candidate should override two negative Phase 3 readouts
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.